Deals
Sanofi Considers U.S. Biotech Targets Including Principia
- French pharmaceutical company scouts for innovative treatments
- Drugmaker discussing several potential deals with advisers
Photographer: Krisztian Bocsi/Bloomberg
This article is for subscribers only.
Sanofi is studying potential acquisitions of U.S. biotechnology companies including Principia Biopharma Inc. as it seeks innovative treatments for clinical areas including multiple sclerosis and immune disorders, people with knowledge of the matter said.
The French drugmaker is working with advisers to study potential deals, the people said, asking not to be identified because the information is private.